{
    "Trade/Device Name(s)": [
        "Yumizen C1200 CRP"
    ],
    "Submitter Information": "HORIBA ABX SAS",
    "510(k) Number": "K191993",
    "Predicate Device Reference 510(k) Number(s)": [
        "K160712",
        "K051564"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DCK"
    ],
    "Summary Letter Date": "October 3, 2019",
    "Summary Letter Received Date": "July 25, 2019",
    "Submission Date": "September 25, 2019",
    "Regulation Number(s)": [
        "21 CFR 866.5270"
    ],
    "Regulation Name(s)": [
        "C-reactive protein immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "C-reactive protein (CRP)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Heparin-lithium tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Yumizen C1200 Clinical chemistry Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Immunoturbidimetric assay"
    ],
    "Methodologies": [
        "Quantitative in vitro diagnostic testing",
        "Immunoturbidimetry"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Yumizen C1200 CRP high sensitive immunoturbidimetric assay for quantitative CRP measurement on Yumizen C1200 analyzer",
    "Indications for Use Summary": "For high sensitive quantitative in vitro determination of C-reactive protein in human serum and plasma to evaluate conditions associated with inflammation in otherwise healthy individuals",
    "fda_folder": "Immunology"
}